Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Refractory Autoimmune Diseases

NCT07038447 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT07038447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07038447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Refractory Autoimmune Diseases
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
July 2, 2025
Completion date
September 30, 2030
Enrollment
52 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus, systemic sclerosis